$0.64
6.77% day before yesterday
Nasdaq, Sep 06, 10:05 pm CET
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Allakos, Inc. Stock price

$0.64
-0.15 18.80% 1M
-0.65 50.71% 6M
-2.09 76.71% YTD
-2.30 78.37% 1Y
-96.45 99.35% 3Y
-84.68 99.25% 5Y
-30.61 97.97% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 6.77%
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Key metrics

Market capitalization $56.49m
Enterprise Value $-26.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.26
P/B ratio (TTM) P/B ratio 0.67
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-187.55m
Free Cash Flow (TTM) Free Cash Flow $-103.33m
Cash position $123.12m
EPS (TTM) EPS $-2.35
P/E forward negative
Short interest 3.70%
Show more

Is Allakos, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Allakos, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Allakos, Inc. forecast:

2x Buy
29%
4x Hold
57%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Allakos, Inc. forecast:

Buy
29%
Hold
57%
Sell
14%

Financial data from Allakos, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 5.04 5.04
43% 43%
-
-5.04 -5.04
43% 43%
-
- Selling and Administrative Expenses 38 38
31% 31%
-
- Research and Development Expense 140 140
22% 22%
-
-183 -183
20% 20%
-
- Depreciation and Amortization 5.04 5.04
43% 43%
-
EBIT (Operating Income) EBIT -188 -188
17% 17%
-
Net Profit -206 -206
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allakos, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allakos, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024.
Neutral
GlobeNewsWire
2 months ago
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile –
Neutral
GlobeNewsWire
3 months ago
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006.
More Allakos, Inc. News

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Head office United States
CEO Robert Alexander
Employees 131
Founded 2012
Website www.allakos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today